You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma

Article info

Article menu

Download PDFPDF

Immunotherapy biomarkers
Original research
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma

Authors

  • Angelika Martina Starzer Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, AustriaDepartment of Medicine I, Christian Doppler Laboratory for Personalized Immunotherapy, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Gerwin Heller Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, AustriaDepartment of Medicine I, Christian Doppler Laboratory for Personalized Immunotherapy, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Erwin Tomasich Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, AustriaDepartment of Medicine I, Christian Doppler Laboratory for Personalized Immunotherapy, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Thomas Melchardt Laboratory for Immunological and Molecular Cancer Research, Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria PubMed articlesGoogle scholar articles
  • Katharina Feldmann Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, AustriaDepartment of Medicine I, Christian Doppler Laboratory for Personalized Immunotherapy, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Teresa Hatziioannou Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, AustriaDepartment of Medicine I, Christian Doppler Laboratory for Personalized Immunotherapy, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Stefan Traint Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Christoph Minichsdorfer Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Ursula Schwarz-Nemec Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Maja Nackenhorst Department of Pathology, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Leonhard Müllauer Department of Pathology, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Matthias Preusser Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, AustriaDepartment of Medicine I, Christian Doppler Laboratory for Personalized Immunotherapy, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Anna Sophie Berghoff Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, AustriaDepartment of Medicine I, Christian Doppler Laboratory for Personalized Immunotherapy, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Thorsten Fuereder Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles

Citation

Starzer AM, Heller G, Tomasich E, et al
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma
Journal for ImmunoTherapy of Cancer 2022;10:e003420. doi: 10.1136/jitc-2021-003420
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.